HC Wainwright restated their buy rating on shares of Opus Genetics (NASDAQ:IRD – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.
Opus Genetics Stock Performance
NASDAQ IRD opened at $0.91 on Tuesday. The firm has a market cap of $29.16 million, a P/E ratio of -0.83 and a beta of 0.28. The firm has a 50-day moving average price of $1.07. Opus Genetics has a 1-year low of $0.81 and a 1-year high of $1.56.
Opus Genetics (NASDAQ:IRD – Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.93). Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The business had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $11.10 million. On average, sell-side analysts anticipate that Opus Genetics will post -1.22 EPS for the current fiscal year.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Recommended Stories
- Five stocks we like better than Opus Genetics
- 3 Stocks to Consider Buying in October
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- How to find penny stocks to invest and trade
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What Do S&P 500 Stocks Tell Investors About the Market?
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
